ClinicalTrials.gg
CompletedNCT00402233Updated May 16, 2014Results posted

A Randomized, Double-blind, Active (Pramipexole 0.5 mg Tid) and Placebo Controlled, Study of Pramipexole Given 0.5 mg and 0.75 mg Bid Over 12-week Treatment in Early Parkinson's Disease (PD) Patients

A Phase 4 interventional study of Pramipexole and Placebo in Parkinson Disease, sponsored by Boehringer Ingelheim. Completed at 39 sites in United States. Open to participants aged 31 Years and older. Per ClinicalTrials.gov, last updated 2014-05-16.

Sponsored by Boehringer Ingelheim · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
312
Allocation
Randomized
Ages
31 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 26 studies testing pramipexole in Parkinson Disease — none open to participants now, none under way, none of them phase 3. Pramipexole · Parkinson Disease.

Enrollment
10th of 26
312 · median 224
Started
2006
with 4 others
Phase 4
10 of 26
none open now
Registered
8th of 26
by date
Lead sponsor
16 of 26
Boehringer Ingelheim

Among the 26 studies testing pramipexole in Parkinson Disease, this one is the 10th largest by enrollment, is one of 5 that started in 2006, is one of 10 in phase 4, and was the 8th registered.

Parkinson Disease

4,578 studies on the registry are indexed under Parkinson Disease; 1,085 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

None of the 26 studies testing pramipexole in Parkinson Disease is open now. The open studies under Parkinson Disease, anywhere →

About pramipexole

Pramipexole: first FDA approval 1997 (MIRAPEX), first EMA approval 1997. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 748 Parkinson Disease studies recruiting now, 311 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 31 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 26 studies testing pramipexole in Parkinson Disease as a file.
02

Study summary

Primary objective: to assess the efficacy of pramipexole given two times daily compared to placebo.

Secondary objectives: to assess the effects of pramipexole on mood, cognition, fatigue, impulse control, daytime sleepiness and nighttime sleep compared to placebo; to compare the tolerability among the treatment groups over 12 weeks

03

Conditions studied

  • Parkinson Disease

Browse trials for

04

Who can participate

Ages eligible
31 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Potential subjects must meet all of the following inclusion criteria to be eligible for enrollment into this study:

  1. Must be willing and able to give .
  2. Must be over 30 years of age at Baseline.
  3. Must have idiopathic Parkinson's disease of less than 7 years duration since diagnosis, characterized by 2 of the following 3 cardinal signs (signs need to be asymmetric): resting tremor, bradykinesia and rigidity.
  4. Must have a Modified Hoehn and Yahr stage \<3.
  5. Should be able to safely tolerate placebo for up to 12 weeks after Baseline.
  6. Must have a negative urine pregnancy test at the Screening Visit and use an adequate method throughout the study if a woman of . Women who are surgically sterile (hysterectomy or tubal ligation) or whose last menstruation was 12 months or more prior to the Screening Visit are considered to be of non-child-bearing potential. Acceptable forms of contraception include oral, implanted, or injected contraceptives intrauterine devices in place for at least 3 months estrogen patch and adequate barrier methods in conjunction with spermicide. Abstinence is considered an acceptable contraceptive regimen.
  7. Must be willing and able to comply with trial procedures. They must be sufficiently proficient in English to understand and complete study instruments.

Exclusion criteria

Exclusion Criteria:

Individuals with any of the following characteristics will not be eligible for entry into this study:

  1. Signs or symptoms suggesting other parkinsonian syndromes.
  2. Use of medications that may cause secondary parkinsonism, including but not limited to: neuroleptics, metaclopramide, alphamethyldopa, flunarizine, methylphenidate, cinnarizine, reserpine, or amphetamines in the last 6 months prior to Baseline Visit.
  3. Use of dopaminergic medications within the last 3 months or for longer than 6 months prior to Baseline Visit.
  4. Presence of dementia by IV criteria (R06-1340) or a (R96-2656) (Appendix 10.1) score less than 26 at Screening Visit.
  5. Presence of major depression, as determined by medical history.
  6. Active epilepsy (i.e., occurrence of a seizure) within the past year prior to Baseline Visit.
  7. Electro Convulsive Therapy in previous 90 days prior to Baseline Visit.
  8. Myocardial infarction within previous 6 months prior to Baseline Visit.
  9. Third degree atrioventricular block or sick sinus syndrome.
  10. Congestive heart failure Class III or IV by classification.
  11. Symptomatic orthostatic hypotension at Screening Visit.
  12. Stereotaxic brain surgery.
  13. liver disease.
  14. Clinically significant renal disease.
  15. Any other clinically significant medical or psychiatric condition (e.g., angina, active neoplasm) that in the judgment of the investigator would interfere with the subjects ability to participate in the study or would jeopardize safe conduct of the study.
  16. Breastfeeding.
  17. Known or intolerability to pramipexole.
  18. Participating in other drug studies or receiving other experimental medications within 30 days of Baseline Visit.
  19. History of drug or alcohol dependency within 6 months of baseline visit.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
312 participants (actual)

Study arms

  • Other
    Placebo

    Drug: Placebo

  • Other
    Pramipexole 0.5 mg Tid

    Pramipexole 0.5 mg tid (three times a day)

    Drug: Pramipexole

  • Other
    Pramipexole 0.5 mg Bid

    Pramipexole 0.5 mg bid (bis in die (two times a day))

    Drug: Pramipexole

  • Other
    Pramipexole 0.75 mg Bid

    Pramipexole 0.75 mg bid (bis in die (two times a day))

    Drug: Pramipexole

Interventions

06

What researchers measure

Primary outcomes

  1. Unified Parkinson's Disease Rating Scale (UPDRS) Total Score

    Total score ranges from zero (best) to 176 (worst), as the sum of Parts I (Mental questions), II (Activity of Daily Living questions), and III (Motor examination)

    Time frame: From baseline to week 12

Secondary outcomes

  1. Modified Hoehn and Yahr Stage

    Score ranges from best 0 (no signs of disease) to worst 5 (wheelchair bound or bedridden unless aided)

    Time frame: From baseline to week 12

  2. Epworth Sleepiness Scale

    Total score ranges from zero (best) to 24 (worst); scale has 8 items, each rated from zero (no chance of dozing) to 3 (high chance of dozing)

    Time frame: From baseline to week 12

  3. Beck Depression Inventory II

    Total score ranges from zero (best) to 63 (worst); scale has 21 items, each rated from zero (absent) to 3 (severe)

    Time frame: From baseline to week 12

07

Results

Posted Jan 13, 2010

Participant flow

Participant flow — Overall Study
MilestonePlaceboMirapex (Pramipexole 0.5 mg Tid)Mirapex (Pramipexole 0.5 mg Bid)Mirapex (Pramipexole 0.75 mg Bid)
Started77808173
Completed72707062
Not completed5101111
Withdrew: Adverse event1799
Withdrew: Protocol violation0100
Withdrew: Withdrawal by subject2122
Withdrew: Worsening of disease under study2000
Withdrew: Worsening of other pre-existing disease0100

Outcome measures

PrimaryUnified Parkinson's Disease Rating Scale (UPDRS) Total Score

Total score ranges from zero (best) to 176 (worst), as the sum of Parts I (Mental questions), II (Activity of Daily Living questions), and III (Motor examination)

Time frame:
From baseline to week 12
Reported as:
Mean · units on a scale
Unified Parkinson's Disease Rating Scale (UPDRS) Total Score
units on a scalePlaceboMirapex (Pramipexole 0.5 mg Tid)Mirapex (Pramipexole 0.5 mg Bid)Mirapex (Pramipexole 0.75 mg Bid)
UPDRS at baseline28.97 ± 11.8227.66 ± 10.7227.21 ± 11.7627.77 ± 9.18
UPDRS at week 1228.19 ± 12.9422.92 ± 10.4422.96 ± 11.9422.65 ± 10.82
Statistical analysis
  • Placebo vs Mirapex (Pramipexole 0.5 mg Tid) · ANCOVA · p = <0.0001 · Mean difference (final values): -4.4 · 95% CI -6.53 to -2.26
  • Placebo vs Mirapex (Pramipexole 0.5 mg Bid) · ANCOVA · p = <0.0001 · Mean difference (final values): -4.41 · 95% CI -6.54 to -2.28
  • Placebo vs Mirapex (Pramipexole 0.75 mg Bid) · ANCOVA · p = <0.0001 · Mean difference (final values): -4.72 · 95% CI -6.91 to -2.52
SecondaryModified Hoehn and Yahr Stage

Score ranges from best 0 (no signs of disease) to worst 5 (wheelchair bound or bedridden unless aided)

Time frame:
From baseline to week 12
Reported as:
Mean · units on a scale
Modified Hoehn and Yahr Stage
units on a scalePlaceboMirapex (Pramipexole 0.5 mg Tid)Mirapex (Pramipexole 0.5 mg Bid)Mirapex (Pramipexole 0.75 mg Bid)
Modified Hoehn and Yahr Stage at baseline1.81 ± 0.481.74 ± 0.51.72 ± 0.51.73 ± 0.51
Modified Hoehn and Yahr Stage at week 121.74 ± 0.541.68 ± 0.521.69 ± 0.521.62 ± 0.56
Statistical analysis
  • Placebo vs Mirapex (Pramipexole 0.5 mg Tid) · Regression, Logistic · Odds ratio (or): 0.893 · 95% CI 0.431 to 1.849
  • Placebo vs Mirapex (Pramipexole 0.5 mg Bid) · Regression, Logistic · Odds ratio (or): 0.885 · 95% CI 0.424 to 1.845
  • Placebo vs Mirapex (Pramipexole 0.75 mg Bid) · Regression, Logistic · Odds ratio (or): 0.687 · 95% CI 0.317 to 1.492
SecondaryEpworth Sleepiness Scale

Total score ranges from zero (best) to 24 (worst); scale has 8 items, each rated from zero (no chance of dozing) to 3 (high chance of dozing)

Time frame:
From baseline to week 12
Reported as:
Mean · units on a scale
Epworth Sleepiness Scale
units on a scalePlaceboMirapex (Pramipexole 0.5 mg Tid)Mirapex (Pramipexole 0.5 mg Bid)Mirapex (Pramipexole 0.75 mg Bid)
Epworth Sleepiness Scale at baseline5.29 ± 3.475.8 ± 3.665.78 ± 3.746.34 ± 4.35
Epworth Sleepiness Scale at week 125.09 ± 3.336.58 ± 3.626.44 ± 4.217.52 ± 5.03
Statistical analysis
  • Placebo vs Mirapex (Pramipexole 0.5 mg Tid) · ANCOVA · p = 0.014 · Mean difference (final values): 1.14 · 95% CI 0.23 to 2.04
  • Placebo vs Mirapex (Pramipexole 0.5 mg Bid) · ANCOVA · p = 0.03 · Mean difference (final values): 1 · 95% CI 0.094 to 1.9
  • Placebo vs Mirapex (Pramipexole 0.75 mg Bid) · ANCOVA · p = 0.0019 · Mean difference (final values): 1.49 · 95% CI 0.56 to 2.43
SecondaryBeck Depression Inventory II

Total score ranges from zero (best) to 63 (worst); scale has 21 items, each rated from zero (absent) to 3 (severe)

Time frame:
From baseline to week 12
Reported as:
Mean · units on a scale
Beck Depression Inventory II
units on a scalePlaceboMirapex (Pramipexole 0.5 mg Tid)Mirapex (Pramipexole 0.5 mg Bid)Mirapex (Pramipexole 0.75 mg Bid)
Beck Depression Inventory II at baseline6.05 ± 6.016.66 ± 5.366.96 ± 5.147.4 ± 5.87
Beck Depression Inventory II at week 125.92 ± 5.835.70 ± 5.145.97 ± 5.146.54 ± 5.19
Statistical analysis
  • Placebo vs Mirapex (Pramipexole 0.5 mg Tid) · ANCOVA · p = 0.39 · Mean difference (final values): -0.55 · 95% CI -1.82 to 0.71
  • Placebo vs Mirapex (Pramipexole 0.5 mg Bid) · ANCOVA · p = 0.37 · Mean difference (final values): -0.57 · 95% CI -1.84 to 0.69
  • Placebo vs Mirapex (Pramipexole 0.75 mg Bid) · ANCOVA · p = 0.48 · Mean difference (final values): -0.47 · 95% CI -1.78 to 0.84

Adverse events

Collected over 12 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—0/77 (0%)27/77 (35.1%)
Mirapex (Pramipexole 0.5 mg Bid)—0/81 (0%)42/81 (51.9%)
Mirapex (Pramipexole 0.75 mg Bid)—2/73 (2.7%)37/73 (50.7%)
Mirapex (Pramipexole 0.5 mg Tid)—1/80 (1.3%)43/80 (53.8%)
Most frequent serious events
Most frequent serious events
EventPlaceboMirapex (Pramipexole 0.5 mg Bid)Mirapex (Pramipexole 0.75 mg Bid)Mirapex (Pramipexole 0.5 mg Tid)
Coronary Artery DiseaseCardiac disorders0/770/811/730/80
Cerebral Infarction, HemiparesisNervous system disorders0/770/811/730/80
ileus (patient stopped drugs 2 days prior)Gastrointestinal disorders0/770/810/731/80
Most frequent other events
Most frequent other events
EventPlaceboMirapex (Pramipexole 0.5 mg Bid)Mirapex (Pramipexole 0.75 mg Bid)Mirapex (Pramipexole 0.5 mg Tid)
somnolenceNervous system disorders4/7714/8116/7320/80
nauseaGastrointestinal disorders7/7718/8111/7315/80
insomniaPsychiatric disorders4/773/819/735/80
dizzinessNervous system disorders7/779/815/739/80
headacheNervous system disorders8/777/816/734/80
constipationGastrointestinal disorders2/778/817/735/80
fatigueGeneral disorders3/776/817/734/80
abnormal dreamsPsychiatric disorders3/773/812/735/80
oedema peripheralGeneral disorders0/772/814/733/80
tremorNervous system disorders4/771/813/730/80

Baseline characteristics

Age, Continuous
Age, Continuous(years)PlaceboMirapex (Pramipexole 0.5 mg Tid)Mirapex (Pramipexole 0.5 mg Bid)Mirapex (Pramipexole 0.75 mg Bid)Total
Mean60.7 ± 1163.7 ± 9.861.6 ± 10.263.1 ± 9.962.3 ± 10.2
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboMirapex (Pramipexole 0.5 mg Tid)Mirapex (Pramipexole 0.5 mg Bid)Mirapex (Pramipexole 0.75 mg Bid)Total
Female19233032104
Male58575141207
08

Study locations

39 sites
  • 248.622.170 Boehringer Ingelheim Investigational Site
    Phoenix, Arizona, United States
  • 248.622.112 Boehringer Ingelheim Investigational Site
    Little Rock, Arkansas, United States
  • 248.622.69 Boehringer Ingelheim Investigational Site
    Fountain Valley, California, United States
  • 248.622.198 Boehringer Ingelheim Investigational Site
    La Jolla, California, United States
  • 248.622.111 Boehringer Ingelheim Investigational Site
    Oxnard, California, United States
  • 248.622.61 Boehringer Ingelheim Investigational Site
    Sacramento, California, United States
  • 248.622.23 Boehringer Ingelheim Investigational Site
    San Diego, California, United States
  • 248.622.73 Boehringer Ingelheim Investigational Site
    San Francisco, California, United States
  • 248.622.108 Boehringer Ingelheim Investigational Site
    Denver, Colorado, United States
  • 248.622.190 Boehringer Ingelheim Investigational Site
    Danbury, Connecticut, United States
  • 248.622.215 Boehringer Ingelheim Investigational Site
    Manchester, Connecticut, United States
  • 248.622.196 Boehringer Ingelheim Investigational Site
    Boca Raton, Florida, United States
  • 248.622.14 Boehringer Ingelheim Investigational Site
    Miami, Florida, United States
  • 248.622.149 Boehringer Ingelheim Investigational Site
    Weston, Florida, United States
  • 248.622.139 Boehringer Ingelheim Investigational Site
    Honolulu, Hawaii, United States
  • 248.622.5 Boehringer Ingelheim Investigational Site
    Chicago, Illinois, United States
  • 248.622.138 Boehringer Ingelheim Investigational Site
    Springfield, Illinois, United States
  • 248.622.87 Boehringer Ingelheim Investigational Site
    Louisville, Kentucky, United States
  • 248.622.207 Boehringer Ingelheim Investigational Site
    New Orleans, Louisiana, United States
  • 248.622.132 Boehringer Ingelheim Investigational Site
    Shreveport, Louisiana, United States
  • 248.622.17 Boehringer Ingelheim Investigational Site
    Boston, Massachusetts, United States
  • 248.622.40 Boehringer Ingelheim Investigational Site
    Boston, Massachusetts, United States
  • 248.622.76 Boehringer Ingelheim Investigational Site
    Boston, Massachusetts, United States
  • 248.622.186 Boehringer Ingelheim Investigational Site
    East Lansing, Michigan, United States
  • 248.622.77 Boehringer Ingelheim Investigational Site
    Omaha, Nebraska, United States
  • 248.622.155 Boehringer Ingelheim Investigational Site
    Lebanon, New Hampshire, United States
  • 248.622.135 Boehringer Ingelheim Investigational Site
    Brooklyn, New York, United States
  • 248.622.216 Boehringer Ingelheim Investigational Site
    Kingston, New York, United States
  • 248.622.202 Boehringer Ingelheim Investigational Site
    New York, New York, United States
  • 248.622.86 Boehringer Ingelheim Investigational Site
    New York, New York, United States
  • 248.622.1 Boehringer Ingelheim Investigational Site
    Rochester, New York, United States
  • 248.622.89 Boehringer Ingelheim Investigational Site
    Cincinnati, Ohio, United States
  • 248.622.20 Boehringer Ingelheim Investigational Site
    Columbus, Ohio, United States
  • 248.622.169 Boehringer Ingelheim Investigational Site
    Hershey, Pennsylvania, United States
  • 248.622.18 Boehringer Ingelheim Investigational Site
    Philadelphia, Pennsylvania, United States
  • 248.622.199 Boehringer Ingelheim Investigational Site
    Houston, Texas, United States
  • 248.622.7 Boehringer Ingelheim Investigational Site
    Houston, Texas, United States
  • 248.622.213 Boehringer Ingelheim Investigational Site
    Spokane, Washington, United States
  • 248.622.104 Boehringer Ingelheim Investigational Site
    Milwaukee, Wisconsin, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2006 and a primary completion of Sep 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2010, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 19, 2006
First posted
Nov 22, 2006
Start
Nov 2006
Primary completionActual
Sep 2008
Results first posted
Jan 13, 2010
Last update
May 16, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 16, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00402233
Responsible party
Sponsor
First posted
Nov 22, 2006
Start date
Nov 2006
Primary completion
Sep 2008
Results posted
Jan 13, 2010
Last update
May 16, 2014

Study contacts

Boehringer Ingelheim
study chair · Boehringer Ingelheim
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pramipexole

Start the discussion